• Opinion
• [Reporter’s Eye] MNC CEOs' response to ‘Korea passing'
• by Eo, Yun-Ho Apr 5, 2021 05:52am

• Company
• Dispute over Eliquis patent will be closed in six years
• by Kim, Jin-Gu Apr 5, 2021 05:51am

• Company
• OB-GYNs fume over the price hike of HPV vaccines
• by Moon, sung-ho Apr 5, 2021 05:51am

• Policy
• Janssen vaccine was confirmed to maintain an immune response
• by Lee, Tak-Sun Apr 5, 2021 05:50am

• Company
• Novartis' Xolair self-administration prescribed at GHs
• by Eo, Yun-Ho Apr 2, 2021 06:06am

• Policy
• Are there less than 20 licensed generic drugs?
• by Lee, Tak-Sun Apr 2, 2021 06:05am

• Policy
• Levitra was withdrawn from the Korean market after 20 years
• by Lee, Tak-Sun Apr 2, 2021 06:05am

• Company
• Aldactone, which was frequently sold out, is resupplied
• by Apr 2, 2021 06:05am

• Company
• Only hope for pancreatic cancer Onivyde seeking for coverage
• by Eo, Yun-Ho Apr 1, 2021 06:08am

• Policy
• Addpharma, entering phase 3 of low-dose Dutasteride
• by Lee, Tak-Sun Apr 1, 2021 06:06am